Features of the use of genetic engineering biological drugs in the treatment of patients with Crohn’s disease
DOI: https://dx.doi.org/10.18565/pharmateca.2023.14.44-48
N.A. Fadeeva, O.V. Knyazev, D.S. Bordin, K.A. Nikolskaya, S.M. Chudnykh, N.A. Dashkina, G.B. Artykova, E.I. Aliev
1) Loginov Moscow Clinical Scientific and Practical Center, Moscow, Russia;
2) Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
3) Tver State Medical University, Tver, Russia;
4) A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
5) Ryzhikh National Medical Research Center of Coloproctology, Moscow, Russia
Background. Genetically engineered biological drugs (GEBDs) have now become the drugs of choice for the treatment of inflammatory bowel diseases (IBD) and have been successfully used since their discovery. This is due to their ability to effectively influence both the IBD pathogenetic mechanisms and symptoms. For the effective and safe use of biological drugs, it is necessary to comply with the indications and rules for their use, and irrational prescription and use of biological drugs can lead to side effects.
Description of a series of clinical cases. The article presents a clinical case of a complicated course of Crohn’s disease (CD) in a young patient, reflects the features of diagnosis and course, and treatment tactics for CD. The problem of loss of response to biological therapy and management features are revealed.
Conclusion. The ability to provide timely and high-tech medical care using modern physical therapy makes it possible to avoid the development of surgical complications for a long time and slow down the progression of IBD.
About the Autors
Corresponding author: Nina A. Fadeeva, Loginov Moscow Clinical Scientific and Practical Center; Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia; n.fadeeva@mknc.ru
Similar Articles